Ophthalmic drug market revenues will reach $21.9 billion in 2015' predicts visiongain

Visiongain predicts that the global market for ophthalmic drugs will reach $21.9bn in 2015. That market generated $17.5bn in 2011, according to Ophthalmic Drugs: World Market Prospects 2013-2023, published in March 2013.
 
 
Ophthalmic Drugs World Market Prospects 2013-2023
Ophthalmic Drugs World Market Prospects 2013-2023
LONDON - April 27, 2013 - PRLog -- The world market for ophthalmic drugs is a profitable niche segment of the healthcare market. Expansion of the ophthalmic market is driven by increasing prevalence of eye disorders. The main causes of visual impairment and sight loss in developed countries are retinal diseases, such as age-related macular degeneration (AMD), diabetic macular edema (DME) and macular edema due to retinal vein occlusion. Worldwide, over 50 million patients are estimated to have AMD, with prevalence rates expected to double by 2020. Glaucoma, the leading cause of irreversible blindness affects an estimated 70 million people worldwide and remains the largest segment of the ophthalmic prescription drugs market. The recent successful launch of Regeneron/Bayer’s Eylea (wet AMD) has given further impetus to this sector.

According to Dr Syed Ahmed, a senior healthcare industry analyst in visiongain: ''Over the next ten years, there will be intense focus in ophthalmic R&D on sustained release implant and injection technologies for retinal diseases. These sustained release formulations will help reduce the frequency of administered injections. Therefore, they offer great potential for driving growth in the ophthalmic sector. Sustained release formulations are likely to benefit market leading drugs such as Lucentis and Eylea.
‘‘Diabetic macular edema (DME) will also be a key player for ophthalmology in the future. The number of people developing type II diabetes is on the increase, and many of these diabetic patients are likely to go on and develop DME. Currently there is no FDA-approved treatment and it is becoming clearer that anti-VEGF therapy will also play an increasing role in the treatment of DME”.

Visiongain forecasts that the overall market for ophthalmic drugs will grow strongly to 2023. The major causes of vision impairment and blindness, and the main targets of pharmacological treatment – glaucoma, AMD and DR, will drive growth in the sector.
Visiongain’s report gives revenue forecasts to 2023 at overall world market, therapeutic submarket and national level. It forecasts world sales for the following segments:
Glaucoma treatments

Anti-allergy, anti-inflammatory and anti-infective agents
Retinal disorder treatments
Dry eye treatments
Other medicines.

That investigation includes analyses of twenty leading products, including Lucentis, Eylea, Visudyne, Xalatan/Xalacom, Patanol and Restasis
The study includes researching trends and forecasting revenues in leading national markets. Countries analysed are the US, Japan, Germany, France, the UK, Spain, Italy, Brazil, India and China. The analysis also discusses opportunities and developments – technological and commercial.
Ophthalmic Drugs: World Market Prospects 2013-2023, adds to visiongain’s range of analytical reports on industries and markets in healthcare.
For sample pages and further information concerning the Visiongain report Ophthalmic Drugs: World Market Prospects 2013-2023 please visit: http://www.visiongain.com/Report/1012/Ophthalmic-Drugs-Wo...

For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials and Automotive sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.
End
Source: » Follow
Email:***@visiongain.com Email Verified
Tags:Ophthalmic, Glaucoma, Amd, Diabetic Macular Edema, Dme
Industry:Biotech, Medical
Location:London City - London, Greater - England
Subject:Reports
Account Phone Number Verified     Disclaimer     Report Abuse
Visiongain PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share